Taking into account baseline (BL) and follow-up (FU) answers.

Questionnaire comprises the following questions:

1. I am hesitant to be treated with IIM.
2. I would consider IIM treatment due to the physician ́s choice.
3. I would consider IIM treatment due to its safety compared to other iron treatment options.
4. I would consider IIM treatment due to its efficacy compared to other iron treatment options.
5. I would consider IIM treatment due to its specific dosing and administration schedule.

Questionnaire comprises the following questions:

1. I am hesitant to treat with IV iron.
2. I would consider IV iron treatment due to the patient ́s desire.
3. I would consider IV iron treatment due to its safety compared to other iron treatment options.
4. I would consider IV iron treatment due to its efficacy compared to other iron treatment options.

And:

1. I am hesitant to treat with IIM.
2. I would consider IIM treatment due to the patient ́s desire.
3. I would consider IIM treatment due to its safety compared to other iron treatment options.
4. I would consider IIM treatment due to its efficacy compared to other iron treatment options.
5. I would consider IIM treatment due to its specific dosing and administration schedule.

Evaluation of kind of iron deficiency.

Institution of diagnosis of IDA/IDNA.

Etiology of iron deficiency.

Method of iron need determination.

Evaluation of dosing intensity of IIM.

Calculated iron need.

Determined iron need.

Difference between administered IIM dose and calculated iron need.

Dose intensities of administration.

Dose intervals of administration.

Reasons for treatment choice of IIM in current patient populations. Reasons could be: efficacy, safety profile, quality of life, patient's preference, physician's preference, comorbidities, convenient dosing, other.

Dose intensity of administration.

Mode of administration.

Duration of infusion.

Rate of physicians and patients with stability or positive change in satisfaction upon IIM treatment.

Red blood cell count

White blood cell count

Hemoglobin

Hematocrit

Platelets

Hemoglobin

Serum ferritin

Transferrin saturation (TfS)

Soluble transferrin receptor (sTfR)

Phosphate level

CRP status.

Number of patients with:

• Treatment-emergent adverse events (maximum grade per patient),
• Grade 3/4 treatment-emergent adverse drug reactions,
• Grade 3/4 treatment-emergent serious adverse events,
• Treatment-emergent serious adverse drug reactions,
• Pre-treatment adverse events,
• Pre-treatment serious adverse events,
• Follow-up adverse events,
• Follow-up serious adverse events.